cefuroxime has been researched along with Kidney Failure, Chronic in 10 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics and transperitoneal transport of cefuroxime were investigated in CAPD patients without peritonitis (n = 6), receiving 500 mg of the drug intravenously (i." | 7.68 | The effect of peritonitis on the transperitoneal transport of cefuroxime in patients on CAPD treatment. ( Dahl, K; Walstad, RA; Widerøe, TE, 1990) |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | 5.28 | Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). ( Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) |
| "The pharmacokinetics and transperitoneal transport of cefuroxime were investigated in CAPD patients without peritonitis (n = 6), receiving 500 mg of the drug intravenously (i." | 3.68 | The effect of peritonitis on the transperitoneal transport of cefuroxime in patients on CAPD treatment. ( Dahl, K; Walstad, RA; Widerøe, TE, 1990) |
| "The efficacy of oral treatment with cephradine in peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD) was compared with that of intraperitoneal cefuroxime over one year." | 3.67 | Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. ( Raman, GV; Searle, M, 1985) |
| "Cefuroxime axetil has been associated with few reported adverse effects." | 2.40 | Bilateral renal cortical necrosis associated with cefuroxime axetil. ( Bailie, GR; Eisele, G; Manley, HJ, 1998) |
| "Cefuroxime is a second-generation cephalosporin that can be used for the treatment of peritoneal dialysis-related peritonitis." | 1.29 | Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. ( Brink, HS; de Jong, PE; Geerlings, W; Huisman, RM, 1994) |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | 1.28 | Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). ( Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) |
| "Patients with peritonitis are now given intraperitoneal netilmicin and intravenous vancomycin." | 1.26 | Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies. ( Bint, AJ; Ferner, RE; Francis, DM; Gokal, R; Goodship, TH; Kerr, DN; Proud, G; Ramos, JM; Ward, MK, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grgurević, I | 1 |
| Pejsa, V | 1 |
| Morović-Vergles, J | 1 |
| Dobrić, I | 1 |
| Gasparović, V | 1 |
| Tudorić, N | 1 |
| Gokal, R | 1 |
| Ramos, JM | 1 |
| Francis, DM | 1 |
| Ferner, RE | 1 |
| Goodship, TH | 1 |
| Proud, G | 1 |
| Bint, AJ | 1 |
| Ward, MK | 1 |
| Kerr, DN | 1 |
| Keogh, B | 1 |
| Ruddock, G | 1 |
| Irwin, J | 1 |
| Watson, A | 1 |
| Keane, CT | 1 |
| Brink, HS | 1 |
| Huisman, RM | 1 |
| Geerlings, W | 1 |
| de Jong, PE | 1 |
| Manley, HJ | 1 |
| Bailie, GR | 1 |
| Eisele, G | 1 |
| Dahl, K | 1 |
| Walstad, RA | 1 |
| Widerøe, TE | 1 |
| Fuiano, G | 1 |
| Sepe, V | 1 |
| Viscione, M | 1 |
| Nani, E | 1 |
| Conte, G | 1 |
| Minelli Bertazzoni, E | 1 |
| Panzetta, G | 1 |
| Searle, M | 1 |
| Raman, GV | 1 |
| Chan, MK | 1 |
| Browning, AK | 1 |
| Poole, CJ | 1 |
| Matheson, LA | 1 |
| Li, CS | 1 |
| Baillod, RA | 1 |
| Moorhead, JF | 1 |
1 review available for cefuroxime and Kidney Failure, Chronic
| Article | Year |
|---|---|
Bilateral renal cortical necrosis associated with cefuroxime axetil.
Topics: Bronchiolitis; Cefuroxime; Cephalosporins; Diabetes Mellitus, Type 2; Female; Humans; Kidney; Kidney | 1998 |
9 other studies available for cefuroxime and Kidney Failure, Chronic
| Article | Year |
|---|---|
Fatal toxic epidermal necrolysis and severe granulocytopenia following therapy with cefuroxime.
Topics: Aged; Agranulocytosis; Anti-Bacterial Agents; Cefuroxime; Fatal Outcome; Female; Humans; Kidney Fail | 2008 |
Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefuroxime; Child; Child, Preschool; Clostridium; Co | 1982 |
Treatment of urinary tract infection with cefuroxime in patients with renal failure.
Topics: Adult; Aged; Cefuroxime; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 1981 |
Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment.
Topics: Administration, Oral; Aluminum Hydroxide; Biological Availability; Cefuroxime; Female; Humans; Kidne | 1994 |
The effect of peritonitis on the transperitoneal transport of cefuroxime in patients on CAPD treatment.
Topics: Ascitic Fluid; Biological Transport; Cefuroxime; Cephalosporins; Humans; Injections, Intraperitoneal | 1990 |
Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD).
Topics: Aztreonam; Cefuroxime; Drug Administration Schedule; Drug Therapy, Combination; Evaluation Studies a | 1989 |
Antibacterial interaction of cefuroxime and serum from uraemic patients.
Topics: Blood Bactericidal Activity; Cefuroxime; Cephalosporins; Humans; Kidney Failure, Chronic; Microbial | 1986 |
Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis.
Topics: Administration, Oral; Cefuroxime; Cephalosporins; Cephradine; Humans; Injections, Intraperitoneal; K | 1985 |
Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis.
Topics: Adult; Aged; Cefuroxime; Cephalosporins; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Mi | 1985 |